Immune to Cancer: The CRI Blog
-
CRI’s James Allison to Receive Prestigious Lasker Award
The Lasker Foundation announced today that James P. Allison, PhD, director of CRI’s Scientific Advisory Council, is…
-
The Coveted Four Stars
For the third consecutive year, Cancer Research Institute earns top rating from Charity Navigator.
-
New Study Suggests a Common Heart Medication Could Help Cancer Patients Live Longer
A new study published yesterday in the journal Cancer suggests that a common medication known as…
-
Jimmy Carter to Receive Immunotherapy for Melanoma
The former president will receive a drug called pembrolizumab, a PD-1-blocking antibody.
-
What Patients Need to Know About Lung Cancer Immunotherapy
Join us on August 21 as Julie Brahmer, MD, discusses the latest research and current treatments for…
-
CRI Awards $29.3 Million to Fund Immunotherapies for All Kinds of Cancer
CRI committed new funds to accelerate research and clinical development.
-
European Regulators Approve Pembrolizumab (Keytruda) as First-line Treatment of Advanced Melanoma
The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.
-
Phase 3 Trial Shows Nivolumab Improves Survival in Advanced Kidney Cancer
The trial ended early because data showed that patients lived longer on nivolumab compared to the standard-of-care…
-
A Cross-Country Biking Trip to Raise Awareness and Funding for Cancer Immunotherapy Research
In memory of his lifelong friend, Bryce, Nolan and his wife, Ileana, decided to bike across country…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.